Skip to main content

ASH 2021 - AML

Magrolimab + Azacitidine-Venetoclax in Newly Diagnosed Patients with High-Risk AML or Those Older/Unfit
ASH 2021 - AML
Conference Correspondent
Triplet combination of the anti-CD47 antibody magrolimab + azacitidine and venetoclax was safe and yielded high CR/CRi rates in newly diagnosed AML patients. Read More ›
Cusatuzumab plus Venetoclax and Azacitidine in Patients with Previously Untreated AML Ineligible for Intensive Chemotherapy
ASH 2021 - AML
Conference Correspondent
Addition of the anti-CD70 antibody cusatuzumab to current standard-of-care venetoclax/azacitidine was generally well-tolerated and showed promising antileukemic activity in elderly patients with untreated AML. Read More ›
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive AML
ASH 2021 - AML
Conference Correspondent
Triplet combination of IMGN632 (an αCD123 ADC) plus azacitidine and venetoclax was associated with a manageable safety profile and promising antileukemic activity in relapsed/refractory AML patients. Read More ›
Venetoclax plus Cladribine/Low-Dose AraC Alternating with 5-Azacitidine in Older and Unfit Patients with Newly Diagnosed AML
ASH 2021 - AML
Conference Correspondent
Low-intensity regimen of venetoclax plus cladribine/low-dose AraC alternating with azacitidine was well-tolerated and produced high response rates with durable MRD-negative remissions among older/unfit patients with newly diagnosed AML. Read More ›
Novel CD7-Targeted CAR-T Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia
ASH 2021 - AML
Conference Correspondent
CD7-targeted CAR-T therapy was associated with a manageable safety profile and produced complete remission in patients with CD7-positive mixed phenotype acute leukemia. Read More ›

Page 2 of 2